Cargando…
Glycodelin as a Serum and Tissue Biomarker for Metastatic and Advanced NSCLC
A major part of non-small cell lung cancer (NSCLC) patients treated with mono- or multimodal concept develop therapy resistance. Despite the abundance of biomarkers investigated in the past, there is still a need for valid NSCLC biomarkers. Glycodelin, an immunosuppressive endometrial protein, has b...
Autores principales: | Schneider, Marc A., Muley, Thomas, Weber, Rebecca, Wessels, Sabine, Thomas, Michael, Herth, Felix J. F., Kahn, Nicolas C., Eberhardt, Ralf, Winter, Hauke, Heussel, Gudula, Warth, Arne, Herold-Mende, Christel, Meister, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315759/ https://www.ncbi.nlm.nih.gov/pubmed/30518088 http://dx.doi.org/10.3390/cancers10120486 |
Ejemplares similares
-
Pathways regulating the expression of the immunomodulatory protein glycodelin in non-small cell lung cancer
por: Weber, Rebecca, et al.
Publicado: (2018) -
Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma
por: Schneider, Marc A., et al.
Publicado: (2016) -
Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives
por: Wessels, Sabine, et al.
Publicado: (2020) -
FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC
por: Richtmann, Sarah, et al.
Publicado: (2019) -
Novel Liquid Biomarker Panels for A Very Early Response Capturing of NSCLC Therapies in Advanced Stages
por: Janke, Florian, et al.
Publicado: (2020)